Dark

Check out our API

FNCH
FINCH THERAPEUTCS GRP INC
stock OTC

Inactive

Mar 23, 2026

7.30USD-39.167%(-4.70)128,123

Pre-market

0.00USD-100.000%(-12.00)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 6, 2022

07:00AM EST Finch Therapeutics Further Strengthens Patent Portfolio with Two GlobeNewswire Inc

Jan 4, 2022

07:00AM EST Finch Therapeutics to Present at the 40th Annual J.P. Morgan GlobeNewswire Inc

Dec 20, 2021

07:08AM EST Finch Therapeutics Appoints Joseph Vittiglio As Chief Business And Legal Officer RTTNews

07:00AM EST Finch Therapeutics Appoints Joseph Vittiglio, JD, as Chief GlobeNewswire Inc

Nov 11, 2021

07:00AM EST Finch Therapeutics Group, Inc. (Finch or Finch Therapeutics) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate virtually in two upcoming investor conferences: GlobeNewswire Inc

Nov 10, 2021

07:56AM EST Finch Therapeutics CMO Zain Kassam To Step Down, Debra Silberg To Become CMO Benzinga

07:42AM EST Finch Therapeutics Group Q3 EPS $(0.21) Up From $(1.22) YoY, Sales $11.34M Up From $1.77M YoY Benzinga

07:21AM EST Finch Therapeutics Q3 Loss Per Share $0.21 Vs Loss $1.22 Last Year RTTNews

07:05AM EST Finch Therapeutics Reports Third Quarter 2021 Financial Results GlobeNewswire Inc

07:00AM EST -- Zain Kassam, MD, MPH to step down as Chief Medical Officer (CMO) and will serve as a special advisor to the company -- Debra Silberg, MD, PhD to transition from clinical advisor to interim CMO GlobeNewswire Inc

Nov 9, 2021

06:31PM EST Finch Therapeutics Announces Data From PRISM-EXT Phase 2 Trial Of CP101 Showing 80.3% Sustained Clinical Cure Rate Through 8 Weeks Benzinga

Oct 25, 2021

07:23AM EDT Finch Therapeutics Presents Positive Data From PRISM3 Trial Of CP101 For Recurrent C. Difficile At ACG Meeting RTTNews

07:00AM EDT -- New data from PRISM3 Phase 2 trial show CP101 demonstrated statistically significant efficacy for prevention of recurrent C. difficile infection and a favorable safety profile through 24 weeks -- Additional PRISM3 microbiome data show CP101 engraftment leads to an increase in intestinal microbiome diversity and sustained clinical cure GlobeNewswire Inc

Oct 12, 2021

07:00AM EDT Finch Therapeutics to Present at the Jefferies Virtual Next GlobeNewswire Inc

Oct 5, 2021

07:10AM EDT Finch Therapeutics Appoints Samuel Allen Hamood To Board RTTNews

07:00AM EDT Finch Therapeutics Appoints Samuel Allen Hamood to its Board of GlobeNewswire Inc

Sep 8, 2021

07:05AM EDT Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer Benzinga

07:00AM EDT Finch Therapeutics Announces the Appointment of Marc Blaustein as GlobeNewswire Inc

Sep 7, 2021

07:00AM EDT Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual GlobeNewswire Inc

Aug 10, 2021

03:54PM EDT Takeda To Lead Finch-Partnered Microbiome IBD Drug Benzinga

09:25AM EDT Finch Therapeutics Q2 Net Loss $15.2 Mln Vs Loss Of $8.3 Mln Last Year RTTNews

07:28AM EDT Finch Therapeutics Group Q2 EPS $(0.32) Up From $(1.02) YoY, Sales $2.83M Up From $2.35M YoY Benzinga

07:11AM EDT Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program Benzinga

07:05AM EDT -- Takeda to accelerate leadership role in advancing FIN-524/TAK-524 ulcerative colitis development program -- Topline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in open label PRISM-EXT trial expected in H2 2021 -- Continued progress advancing development programs, withclinical data across multiple programs anticipated in 2022 GlobeNewswire Inc

07:00AM EDT -- Finch to transfer FIN-524 program to Takeda for clinical development -- Finch and Takeda to continue discovery efforts targeting Crohns disease GlobeNewswire Inc

Jun 28, 2021

07:00AM EDT Finch Therapeutics Added to Russell 2000 and Russell 3000 Indexes GlobeNewswire Inc

May 28, 2021

07:00AM EDT Finch Therapeutics Group, Inc. (Finch or Finch Therapeutics) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in two upcoming virtual investor conferences: GlobeNewswire Inc

May 13, 2021

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

07:10AM EDT Finch Therapeutics Group Q1 EPS $(1.00), Same YoY Benzinga

07:00AM EDT Finch Therapeutics Reports First Quarter 2021 Financial Results GlobeNewswire Inc

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

May 11, 2021

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 6, 2021

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

07:00AM EDT Finch Therapeutics to Participate in the BofA Securities 2021 GlobeNewswire Inc

Apr 28, 2021

07:26AM EDT The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping Benzinga

Apr 27, 2021

07:00AM EDT Finch Therapeutics Appoints Susan E. Graf to Board of Directors GlobeNewswire Inc

Apr 22, 2021

08:09AM EDT The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs Benzinga

Apr 21, 2021

07:31AM EDT The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue Benzinga

Apr 15, 2021

07:00AM EDT Finch Therapeutics to Participate in the Jefferies GlobeNewswire Inc

Apr 13, 2021

12:08PM EDT Finch Therapeutics Group shares were trading higher after multiple firms initiated coverage on the stock with a Bullish rating. Benzinga

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2021 Benzinga

08:54AM EDT Evercore ISI Group Initiates Coverage On Finch Therapeutics Group with Outperform Rating, Announces Price Target of $34 Benzinga

08:21AM EDT Jefferies Initiates Coverage On Finch Therapeutics Group with Buy Rating, Announces Price Target of $29 Benzinga

07:02AM EDT B of A Securities Initiates Coverage On Finch Therapeutics Group with Buy Rating, Announces Price Target of $25 Benzinga

Apr 10, 2021

09:19AM EDT The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight Benzinga

Mar 28, 2021

08:15AM EDT The Past Week's Notable Insider Buys: Babcock & Wilcox, Designer Brands And More Benzinga

Mar 25, 2021

07:58AM EDT The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut Benzinga

Mar 24, 2021

08:59AM EDT The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping Benzinga

Mar 23, 2021

08:18AM EDT The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO Benzinga

Mar 22, 2021

12:28PM EDT The IPO Market Had A Busy Week Benzinga

Mar 19, 2021

10:39AM EDT Finch Therapeutics Shares Open For Trade At $20.45; IPO Priced At $17/Share Benzinga

09:29AM EDT Finch Therapeutics Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $17/Share Benzinga

Mar 18, 2021

10:32PM EDT Finch Therapeutics Announces Pricing of Upsized Initial Public GlobeNewswire Inc

Share